Catalog No.
RHK18501
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Alpaca
Isotype
VHH-8His-Cys-tag
Clonality
Monoclonal
Target
T-cell surface glycoprotein CD8 alpha chain, CD8a, T-lymphocyte differentiation antigen T8/Leu-2, MAL, CD8A
Concentration
1.72 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Purified by Nickel column.
Accession
P01732
Applications
ELISA
Form
Liquid
Storage buffer
30 mM histidine pH 5.8,10% sucrose, 0.02% Tween 80
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
SAA2076
A novel NKG2A alpaca nanobody targeting immune checkpoint blockade for the treatment of malignant melanoma., PMID:40370819
Expression of the TIGIT axis and the CD39/CD73 purinergic pathway in bone metastasis-derived immune cells., PMID:40274631
68Ga-NOTA-m-SNA006: A Next-Generation CD8-Targeting Nanobody Probe to Enhance Renal and Hepatic Clearance in Noninvasive ImmunoPET Imaging., PMID:40266244
Modular Design of T Cell Nanoengagers for Tumor Immunotherapy via Genetically Engineered Lipid-Tagged Antibody Fragments., PMID:40259502
Engineered Genetic Circuits Activated by Bezafibrate Improve ESC-Based TAA Cancer Vaccine Efficacy and PD-L1 Nanobody Therapy., PMID:40245119
GRP78 Nanobody-Directed Immunotoxin Activates Innate Immunity Through STING Pathway to Synergize Tumor Immunotherapy., PMID:40135833
AWT020: a novel fusion protein harnessing PD-1 blockade and selective IL-2 Cis-activation for enhanced anti-tumor immunity and diminished toxicity., PMID:40046051
Deep-Red and Ultrafast Photocatalytic Proximity Labeling Empowered In Situ Dissection of Tumor-Immune Interactions in Primary Tissues., PMID:40036744
Fc-competent TIGITx4-1BB bispecific antibody exerts potent long-lasting antitumor activity by potentiating CD8+ T cell activity and Fcγ receptor-mediated modulation of the tumor microenvironment., PMID:40010766
A Highly Sensitive Immunoassay to Enable Quantification of a Nanobody-Based Imaging Agent in Human Serum., PMID:39900849
Oncolytic vaccinia virus armed with anti-CD47 nanobody elicit potent antitumor effects on multiple tumor models via enhancing innate and adoptive immunity., PMID:39794937
Human dose-escalation study of PET imaging CD8+ T-cell infiltration in solid malignancies with [68Ga]Ga -NODAGA-SNA006., PMID:39653817
Fusing a Novel Anti-CTLA-4 Nanobody to the IgG1 Fc Region Strengthens Its Ability to Induce CD8+ T Cell-Mediated Immune Responses Against Solid Tumors., PMID:39588259
Targeted degradation of the HPV oncoprotein E6 reduces tumor burden in cervical cancer., PMID:39464070
A novel anti-CTLA-4 nanobody-IL12 fusion protein in combination with a dendritic cell/tumour fusion cell vaccine enhances the antitumour activity of CD8+ T cells in solid tumours., PMID:39427185
Programmable Circular Multivalent Nanobody-Targeting Chimeras (mNbTACs) for Multireceptor-Mediated Protein Degradation and Targeted Drug Delivery., PMID:39402961
Specific imaging of CD8 + T-Cell dynamics with a nanobody radiotracer against human CD8β., PMID:39218831
A novel doxorubicin/CTLA-4 blocker co-loaded drug delivery system improves efficacy and safety in antitumor therapy., PMID:38824143
Nanobody-based CAR NK cells for possible immunotherapy of MICA+ tumors., PMID:38756234
Expression of CD39 is associated with T cell exhaustion in ovarian cancer and its blockade reverts T cell dysfunction., PMID:38737794
Discovery and preclinical development of a therapeutically active nanobody-based chimeric antigen receptor targeting human CD22., PMID:38596311
MICA-specific nanobodies for diagnosis and immunotherapy of MICA+ tumors., PMID:38550583
Specific Targeting of Zinc Transporter LIV-1 with Immunocytokine Containing Anti-LIV-1 VHH and Human IL-2 and Evaluation of its In vitro Antitumor Activity., PMID:38482625
Improved antitumor effects elicited by an oncolytic HSV-1 expressing a novel B7H3nb/CD3 BsAb., PMID:38428724
Methods for studying P2X4 receptor ion channels in immune cells., PMID:38311008
Reprogramming tumor-associated macrophages by a dually targeted milk exosome system as a potent monotherapy for cancer., PMID:38184235
Nanobody-mediated SPECT/CT imaging reveals the spatiotemporal expression of programmed death-ligand 1 in response to a CD8+ T cell and iNKT cell activating mRNA vaccine., PMID:37908728
Dendritic Cell-Mediated Cross-Priming by a Bispecific Neutralizing Antibody Boosts Cytotoxic T Cell Responses and Protects Mice against SARS-CoV-2., PMID:37863812
Neutrophil-Mediated Tumor-Targeting Delivery System of Oncolytic Bacteria Combined with ICB for Melanoma Lung Metastasis Therapy., PMID:37565362
A novel CTLA-4 blocking strategy based on nanobody enhances the activity of dendritic cell vaccine-stimulated antitumor cytotoxic T lymphocytes., PMID:37419930
Local delivery of optimized nanobodies targeting the PD-1/PD-L1 axis with a self-amplifying RNA viral vector induces potent antitumor responses., PMID:37001752
Human VH-based chimeric antigen receptor T cells targeting glypican 3 eliminate tumors in preclinical models of HCC., PMID:36691969
INBRX-120, a CD8α-targeted detuned IL-2 that selectively expands and activates tumoricidal effector cells for safe and durable in vivo responses., PMID:36653071
Construction of stable membranal CMTM6-PD-L1 full-length complex to evaluate the PD-1/PD-L1-CMTM6 interaction and develop anti-tumor anti-CMTM6 nanobody., PMID:36418428
Development of an 18F-labeled anti-human CD8 VHH for same-day immunoPET imaging., PMID:36346438
PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way., PMID:36253000
Macrophage-mediated tumor-targeted delivery of engineered Salmonella typhi murium VNP20009 in anti-PD1 therapy against melanoma., PMID:36213533
Dendritic cells modified by tumor associated antigen SMP30 have enhanced antitumor effect against mouse hepatocarcinoma cells in vitro and in vivo., PMID:36105050
Programmable Attenuation of Antigenic Sensitivity for a Nanobody-Based EGFR Chimeric Antigen Receptor Through Hinge Domain Truncation., PMID:35935988
Pilot study of a novel nanobody 68 Ga-NODAGA-SNA006 for instant PET imaging of CD8+ T cells., PMID:35829748
Robust delivery of RIG-I agonists using extracellular vesicles for anti-cancer immunotherapy., PMID:35430766
Imaging and therapeutic targeting of the tumor immune microenvironment with biologics., PMID:35351469
Combination therapy with Nab-paclitaxel and the interleukin-15 fused with anti-human serum albumin nanobody as a synergistic treatment for colorectal cancer., PMID:35019820
Noninvasive Immuno-PET Imaging of CD8+ T Cell Behavior in Influenza A Virus-Infected Mice., PMID:34804069
CS1-specific single-domain antibodies labeled with Actinium-225 prolong survival and increase CD8+ T cells and PD-L1 expression in Multiple Myeloma., PMID:34777918
Selective IL-1 activity on CD8+ T cells empowers antitumor immunity and synergizes with neovasculature-targeted TNF for full tumor eradication., PMID:34772757
An engineered IL-21 with half-life extension enhances anti-tumor immunity as a monotherapy or in combination with PD-1 or TIGIT blockade., PMID:34735918
A class II MHC-targeted vaccine elicits immunity against SARS-CoV-2 and its variants., PMID:34654739
A new PD-1-specific nanobody enhances the antitumor activity of T-cells in synergy with dendritic cell vaccine., PMID:34562519
Endoglin-Aptamer-Functionalized Liposome-Equipped PD-1-Silenced T Cells Enhance Antitumoral Immunotherapeutic Effects., PMID:34511903
For research use only. Not for human or drug use.
